Aslan Pharmaceuticals Company Leadership
| ASLN Stock | USD 0.45 0.03 7.14% |
Aslan Pharmaceuticals employs about 35 people. The company is managed by 7 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 5.0 employees per reported executive. Analysis of Aslan Pharmaceuticals' management performance can provide insight into the firm performance.
| Kiran Asarpota President Vice President-Finance |
Aslan |
Aslan Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.6371) % which means that it has lost $0.6371 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2664) %, meaning that it created substantial loss on money invested by shareholders. Aslan Pharmaceuticals' management efficiency ratios could be used to measure how well Aslan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of May 2024, Return On Tangible Assets is likely to drop to -1.89. In addition to that, Return On Capital Employed is likely to grow to -3.61. At this time, Aslan Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 7th of May 2024, Other Current Assets is likely to grow to about 2.8 M, while Net Tangible Assets are likely to drop about 7.1 M.As of the 7th of May 2024, Common Stock Shares Outstanding is likely to drop to about 8.4 M. In addition to that, Net Loss is likely to drop to about (62 M)
Aslan Pharmaceuticals Workforce Comparison
Aslan Pharmaceuticals Ltd is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 41.0. Aslan Pharmaceuticals totals roughly 35.0 in number of employees claiming about 85% of equities under Health Care industry.
Aslan Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Aslan Pharmaceuticals Price Series Summation is a cross summation of Aslan Pharmaceuticals price series and its benchmark/peer.
Aslan Pharmaceuticals Notable Stakeholders
An Aslan Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aslan Pharmaceuticals often face trade-offs trying to please all of them. Aslan Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aslan Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kiran Asarpota | Vice President-Finance | Profile | |
| Alexandre MD | Chief Officer | Profile | |
| Stephen Doyle | Chief Officer | Profile | |
| Charlie Hsu | Investor Director | Profile | |
| ChiChin Wang | IR Director | Profile | |
| Ben Goodger | General Counsel | Profile | |
| Carl EMBA | CEO Founder | Profile |
About Aslan Pharmaceuticals Management Performance
The success or failure of an entity such as Aslan Pharmaceuticals often depends on how effective the management is. Aslan Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aslan management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aslan management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.80) | (1.89) | |
| Return On Capital Employed | (3.80) | (3.61) | |
| Return On Assets | (1.80) | (1.89) | |
| Return On Equity | 3.33 | 1.94 |
The data published in Aslan Pharmaceuticals' official financial statements usually reflect Aslan Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Aslan Pharmaceuticals. For example, before you start analyzing numbers published by Aslan accountants, it's critical to develop an understanding of what Aslan Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Aslan Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aslan Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Aslan Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aslan Pharmaceuticals Ltd. Please utilize our Beneish M Score to check the likelihood of Aslan Pharmaceuticals' management manipulating its earnings.
Aslan Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Aslan Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aslan Pharmaceuticals within its industry.Aslan Pharmaceuticals Manpower Efficiency
Return on Aslan Pharmaceuticals Manpower
| Revenue Per Employee | 342.9K | |
| Revenue Per Executive | 1.7M | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 6.3M | |
| Working Capital Per Employee | 314.7K | |
| Working Capital Per Executive | 1.6M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Revenue Per Share 0.729 | Return On Assets (0.64) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.